Financial reports
10-K
2023 FY
Annual report
21 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q3
Quarterly report
10 Aug 23
10-Q
2022 Q3
Quarterly report
4 May 23
ARS
2022 FY
Annual report to shareholders
25 Apr 23
10-K
2022 FY
Annual report
21 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
17 Mar 22
Current reports
8-K
Other Events
5 Apr 24
8-K
Regulation FD Disclosure
1 Apr 24
8-K
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial
21 Mar 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Regulation FD Disclosure
27 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
14 Nov 23
8-K
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates
9 Nov 23
8-K
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome
31 Oct 23
8-K
X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors
18 Oct 23
8-K
X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome
5 Sep 23
Registration and prospectus
S-8
Registration of securities for employees
25 Jan 24
S-3
Shelf registration
11 Aug 23
S-8
Registration of securities for employees
11 Aug 23
424B3
Prospectus supplement
20 Jun 23
S-3
Shelf registration
9 Jun 23
D
$65.02 mm in equity / options / securities to be acquired, sold $65.02 mm, 22 investors
1 Jun 23
S-8
Registration of securities for employees
20 Jan 23
424B5
Prospectus supplement for primary offering
8 Dec 22
424B5
Prospectus supplement for primary offering
6 Dec 22
424B3
Prospectus supplement
5 Aug 22
Proxies
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEFA14A
Additional proxy soliciting materials
25 Apr 23
DEF 14A
Definitive proxy
25 Apr 23
DEF 14A
Definitive proxy
11 Aug 22
PRE 14A
Preliminary proxy
1 Aug 22
DEFA14A
Additional proxy soliciting materials
25 Apr 22
DEF 14A
Definitive proxy
25 Apr 22
DEFA14A
Additional proxy soliciting materials
20 Apr 21
DEF 14A
Definitive proxy
20 Apr 21
DEFA14A
Additional proxy soliciting materials
12 May 20
Other
EFFECT
Notice of effectiveness
25 Aug 23
CORRESP
Correspondence with SEC
22 Aug 23
UPLOAD
Letter from SEC
21 Aug 23
EFFECT
Notice of effectiveness
21 Jun 23
UPLOAD
Letter from SEC
16 Jun 23
CORRESP
Correspondence with SEC
16 Jun 23
EFFECT
Notice of effectiveness
8 Aug 22
CORRESP
Correspondence with SEC
3 Aug 22
UPLOAD
Letter from SEC
2 Aug 22
EFFECT
Notice of effectiveness
13 May 22
Ownership
4
Arthur Taveras
11 Mar 24
4
Paula Ragan
11 Mar 24
4
Adam S. Mostafa
11 Mar 24
4
Mary DiBiase
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
4/A
Christophe Arbet-Engels
28 Feb 24
4
Christophe Arbet-Engels
16 Feb 24